Trial · NCT07883356
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
NCT07883356, Phase 2, Not yet recruiting, Region Skane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO). Trials, record NCT07883356. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883356
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
- NCT number
- NCT07883356
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 554 participants, estimated
- Lead sponsor
- Region Skane
- Conditions
Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy, Graves' Orbitopathy, Graves' Disease, Graves' Hyperthyroidism, Graves´ Disease, Graves´ Ophthalmopathy, Graves' Ophthalmopathy (GO), Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid-Associated Ophthalmopathy
- Interventions
- Atorvastatin
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Development of Active Graves' Orbitopathy | 12 months after randomization | Proportion of participants who develop active Graves' orbitopathy, defined as a Clinical Activity Score (CAS) ≥3, as assessed by standardized ophthalmological evaluation. |
| Secondary | Development of Active Graves' Orbitopathy at 3, 6, 9, 15, and 18 Months | 3, 6, 9, 15, and 18 months after randomization | Proportion of participants who develop active Graves' orbitopathy, defined as a Clinical Activity Score (CAS) ≥3, as assessed by standardized ophthalmological evaluation. |
| Secondary | Genetic Factors Associated With Response to Atorvastatin | Baseline (genotyping) and 12 months (CAS) | Genotype frequencies for CYR61 rs3753793 and rs12756618, ZFP36 rs1057745, SCD rs1393491, CTLA4 rs231775, TSHR rs179247, and SLCO1B1 rs4149056 will be determined. Genotype frequencies will be compared between participants with and without active Graves' ophthalmopathy, defined as a Clinical Activity Score (CAS) ≥3 at 12 months. |
| Secondary | Time to Development of Active Graves' Orbitopathy | From diagnosis through 18 months | Time from GD diagnosis to the first occurrence of active Graves' orbitopathy, defined as a Clinical Activity Score (CAS) ≥3. |
| Secondary | Correlations between circulating biomarker levels and Graves' ophthalmopathy clinical activity score | Baseline, 3 months, 12 months, and 18 months | Spearman's rank correlation coefficients will be calculated separately for each circulating biomarker and the seven-item Clinical Activity Score (CAS) at each visit. The biomarker panel comprises multimerin-1 (MMRN1), IgG Fc-binding protein (FCGBP), cadherin-5 (CDH5), complement factor H-related protein 5 (CFHR5), apolipoprotein D (APOD), C-X-C motif chemokine ligand 10 (CXCL10/IP-10), and interleukin-6 (IL-6). These analyses are exploratory. |
| Secondary | Maximum Clinical Activity Score During Follow-up | From randomization through 18 months | The highest Clinical Activity Score (CAS) recorded for each participant during the study follow-up period. Higher scores indicate greater inflammatory activity of Graves' orbitopathy. |
| Secondary | Need for Treatment for Graves' Orbitopathy | From randomization through 18 months | Proportion of participants requiring treatment for Graves' orbitopathy, including systemic glucocorticoids, orbital radiotherapy, biologic treatment, or other disease-specific treatment because of development or progression of Graves' orbitopathy. |
| Secondary | Change in Graves' Orbitopathy-Specific Quality of Life | Baseline, 12 months, and 18 months | Change in Graves' orbitopathy-related quality of life assessed using the Graves' Orbitopathy Quality of Life questionnaire (GO-QoL). The questionnaire assesses visual functioning and appearance-related impact of Graves' orbitopathy. |
| Secondary | Change in Thyroid-Related Quality of Life | Baseline, 12 months, and 18 months | Change in thyroid-related symptoms and quality of life assessed using the ThyPRO questionnaire. |
| Secondary | Change in Thyrotropin Receptor Antibody Levels | Baseline, 6, 12, 18 months | Change in serum thyrotropin receptor antibody (TRAb) levels from baseline during follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883356
GET https://conductscience.org/api/trials/v1/NCT07883356/registered